Clinical Study Of Influenza Agreement Prescription Combined With Oseltamivir In The Treatment Of Influenza(Wind-heat Sydrome)

Objective: To observe the clinical therapeutic efficacy and safety of influenza agreement prescription combined with oseltamivir in the treatment of influenza(wind-heat sydrome).Methods: A randomized control method was used to divide 72 patients who attended the emergency department,respiratory department,and fever clinic of Mianyang Hospital of Chengdu University of Traditional Chinese Medicine and Mianyang First People’s Hospital from November 2021 to December 2022,who were eligible for influenza(wind-heat offensive evidence),into 36 patients in the treatment group and 36 patients in the control group.Both groups were given oral oseltamivir phosphate capsules(75mg/capsule,twice daily)as an antiviral,and the treatment group added the influenza protocol prescription(Ingredients:Honeysuckle 20 g,Forsythia 15 g,Scutellaria 15 g,Panax quinquefolium 20 g,Fructus tigrinus 20 g,Thornbush 10 g,Fructus defensa 10 g,Perilla frutescens 10 g,Atractylodes macrocephala 15 g,Arctium lappa 10 g,Radix Platycodon 10 g,Radix glycyrrhizae6g;Chinese medicine no-decoction form,9.6g/bag,2 bags each time,3 times daily)on top of this,and the course of treatment was 5 days in both groups.The patients were observed for the time of onset of fever reduction and complete fever reduction,fever reduction at 24,48 and 72 hours after enrollment,symptom scores before and after the end of treatment,the conversion of influenza virus antigen and safety indexes such as blood routine(WBC,N%,LYM%)and liver and kidney function(ALT,AST,Crea),and the data obtained were analyzed by applying SPSS.Results:(1)General: A total of 72 patients who met the criteria were included in this study,and at the end of treatment,1 case was excluded and 2 cases were shed from the treatment group,resulting in the inclusion of 33 cases;1 case was excluded from the control group,resulting in the inclusion of 35 cases.Statistical analysis of age,gender,symptom score,epidemiological exposure history,type of influenza infection,and fever in the two groups showed no significant differences in the above aspects(P>0.05),and the data were comparable.(2)Symptom scores: The total symptom scores of patients in both groups were significantly lower after treatment than before treatment,and there were statistical differences between and within the two groups(P<0.05).Both groups had therapeutic effects on influenza(wind-heat offending the body),and the treatment group was significantly more effective than the control group in relieving muscle aches,nasal congestion,sore throat,cough,headache,and body fatigue,and the differences were statistically significant(P<0.05).(3)Body temperature: the onset of antipyretic effect time and complete antipyretic time were shorter in the treatment group than in the control group,and the24-hour and 48-hour antipyretic rates were higher in the treatment group than in the control group,and the differences were statistically significant(P<0.05).(4)The total effective rate of the treatment group was higher than that of the control group,and the difference was statistically significant(P<0.05).(5)At the end of the treatment,the treatment in both groups did not affect the patients’ blood routine(WBC,N%,LYM%),liver function(ALT,AST)and kidney function(Crea)indexes,and no adverse effects were observed.Conclusion: The clinical efficacy of influenza agreement prescription combined with oseltamivir in the treatment of influenza(wind-heat sydrome)is remarkable,which can improve the symptoms more quickly,and its fever-reducing effect is fast,with high safety and no adverse effects.